Seah Steve K L, Gazzard Gus, Aung Tin
Singapore National Eye Centre, Singapore, Republic of Singapore.
Ophthalmology. 2003 May;110(5):888-94. doi: 10.1016/S0161-6420(03)00088-5.
To determine the intermediate-term efficacy and safety of Baerveldt glaucoma implants in Asian eyes with complicated glaucoma.
Retrospective, nonrandomized, comparative trial.
One hundred twenty-four Asian patients (124 eyes) with complicated glaucoma.
Implantation of 54 250-mm(2) and 70 350-mm(2) Baerveldt glaucoma drainage implants at Singapore National Eye Center from 1994 through 1999.
Intraocular pressure, number of glaucoma medications, and complications.
The mean follow-up period was 33.4 +/- 14.4 months (mean +/- SD; range, 12-72 months). Intraocular pressure (IOP) was reduced from a mean preoperative IOP of 36.5 +/- 10.7 mmHg (range, 21-80 mmHg) to 15.3 +/- 6.0 mmHg (range, 1-34 mmHg), and the number of glaucoma medications decreased from 2.6 +/- 0.6 (range, 1-5) before the time of surgery to 0.5 +/- 0.9 (range, 0-4) medications at last follow-up. Overall, there were 67 eyes (54%) that were classified as complete successes, 27 eyes (22%) that were qualified successes, and 30 eyes that failed (24%). Postoperative complications occurred in 43 eyes (34.7%), and 21 eyes (17%) required further surgical intervention and revision. There was no statistically significant difference between the 250-mm(2) and 350-mm(2) type of implants in terms of success rates, final IOP, number of medications, and rates of complications. After adjusting for gender, preoperative IOP, and length of follow-up, increasing age (odds ratio [OR], 1.05; 95% confidence interval [CI], 1.01-1.09; P = 0.02) and the number of previous operations performed before implant surgery (OR, 1.57; 95% CI, 1.07-2.31; P = 0.01) were found to be correlated positively with failure.
In Asian eyes with complicated glaucoma, Baerveldt glaucoma implants achieve stable and satisfactory IOP reduction with low incidence of complications in the intermediate term after surgery.
确定Baerveldt青光眼植入物用于亚洲复杂性青光眼患者的中期疗效和安全性。
回顾性、非随机对照试验。
124例亚洲复杂性青光眼患者(124只眼)。
1994年至1999年期间,在新加坡国立眼科中心植入54枚250平方毫米和70枚350平方毫米的Baerveldt青光眼引流植入物。
眼压、青光眼药物使用数量及并发症。
平均随访时间为33.4±14.4个月(均值±标准差;范围12 - 72个月)。眼压从术前平均36.5±10.7mmHg(范围21 - 80mmHg)降至15.3±6.0mmHg(范围1 - 34mmHg),青光眼药物使用数量从手术前的2.6±0.6(范围1 - 5)种降至末次随访时的0.5±0.9(范围0 - 4)种。总体而言,67只眼(54%)为完全成功,27只眼(22%)为合格成功,30只眼失败(24%)。43只眼(34.7%)出现术后并发症,21只眼(17%)需要进一步手术干预和修复。250平方毫米和350平方毫米两种类型的植入物在成功率、最终眼压、药物使用数量及并发症发生率方面无统计学显著差异。校正性别、术前眼压和随访时间后,发现年龄增加(比值比[OR],1.05;95%置信区间[CI],1.01 - 1.09;P = 0.02)及植入手术前既往手术次数(OR,1.57;95%CI,1.07 - 2.31;P = 0.01)与失败呈正相关。
对于亚洲复杂性青光眼患者,Baerveldt青光眼植入物在术后中期可实现稳定且令人满意的眼压降低,并发症发生率低。